Floatz logo

Tacrolimus

Hematopoietic And Lymphoid System Neoplasm

Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →
Floatz Rating
B63/100
Confidence
Indicative
v0.2
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07524530CT.gov
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
—Not Yet Recruiting———
NCT05088356CT.gov
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
—Active Not Recruiting———
NCT02145403CT.gov
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
—Completed———
NCT01246206CT.gov
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
—Completed———
NCT01203722CT.gov
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
—Completed———
NCT01010217CT.gov
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
—Completed———
NCT00489203CT.gov
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
—Completed———
NCT00144703CT.gov
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematopoietic And Lymphoid System Neoplasm

AssetSponsorPhaseRating
Tacrolimus (this asset)National Cancer Institute (NCI)P2B · 63
AdriamycinOHSU Knight Cancer InstituteP4BBB
DexasoneCity of Hope Medical CenterP3BB
TeclistamabJanssen Pharmaceutical K.K.P2BB
Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdP3BB
CyclophosphamideNational Cancer Institute (NCI)P3BB
BortezomibOHSU Knight Cancer InstituteP4BB
EtoposideCiusss de L'Est de l'Île de MontréalP2BB
PembrolizumabVividion Therapeutics, Inc.P3BB

+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort

Other indications for Tacrolimus

IndicationSponsorPhaseRating
Disease Related To Transplantation—P4BBB · 79
Disease Related To Solid Organ Transplantation—P4BBB · 76
Beta-Thalassemia Major—P4BBB · 75

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Tacrolimus in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/tacrolimus-hematopoietic-and-lymphoid-system-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →